YFM Equity Partners invested in the company through the Seraphim Capital Fund and British Smaller Companies VCT2 alongside a syndicate of other existing investors including Oxford Capital Partners, IQ Capital and NESTA.

The finance will be used to commercialise Sirigen’s “high sensitivity flourescence” technology, which is designed to enhance the performance of diagnostic tools used to analyse and manage diseases such as HIV and leukaemia.

In 2000, the Nobel Prize in Chemistry was awarded for the discovery of a unique class of conducting polymer materials, which are the foundation of Sirigen’s technology.

The latest funding comes nearly a year after a previous financing that totalled £3.83 million last October, which was announced in tandem with the appointment of four new directors. The business was formed in 2003 and has offices in Ringwood, Hampshire, UK and in San Diego, US.

Sirigen chairman David Evans comments, ‘We have passed an important milestone launching our Brilliant Violet product on market in May 2010 through BioLegend. We have seen strong demand and we have a pipeline of further groundbreaking products imminently being launched.’